Innoviva reports Q4 2022 royalties of $54.7M, pre-tax loss of $64.7M on $85.4M fair-value decline

Innoviva, Inc.

2022-FY EPS reported $2.37 revenue$331,339,000

Gross royalty revenues of $54.7M from GSK for RELVAR/BREO and ANORO ELLIPTA in Q4 2022.
Income before taxes was a loss of $64.7M vs. income of $56.5M in Q4 2021, driven by $85.4M decline in fair value of investments.
Net product sales of $14.6M from GIAPREZA and XERAVA in Q4 2022.
Board authorized $100M share repurchase program; $30M convertible debt facility with Armata closed in January 2023.
FDA granted priority review for SUL-DUR NDA; PDUFA date May 29, 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Innoviva, Inc. reported financial results for the fourth quarter ended December 31, 2022.

Period: the fourth quarter ended December 31, 2022
Result: reported results

Exact text from the filing

On February 28, 2023, Innoviva, Inc. (the "Company") issued a press release regarding its results of operations and financial condition for the quarter ended December 31, 2022.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Innoviva, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-026810

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.